Proteome Sciences（PRM）株式概要プロテオーム・サイエンシズ社は、米国、英国、欧州連合、および国際的にタンパク質バイオマーカーの同定、検証、応用のための受託研究サービスを提供。 詳細PRM ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性2/6配当金0/6リスク分析過去5年間で収益は年間59.7%減少しました。 マイナスの株主資本 意味のある時価総額がありません ( £5M )過去1年間で株主の希薄化が進んだ +1 さらなるリスクすべてのリスクチェックを見るPRM Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUK£Current PriceUK£0.021141.4% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-3m8m2016201920222025202620282031Revenue UK£2.9mEarnings UK£372.8kAdvancedSet Fair ValueView all narrativesFeatured narrative•Pharmaceuticals & Biotech opportunityGain Therapeuticsabout 1 month ago author updated this narrativeLOFair Value from Lou_BaseneseUS$7.676.1% 割安 内在価値ディスカウントThe Market Is Sleeping on This Parkinson's Biotech - And I Think That's a MistakeGain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read full narrative4kusers have viewed this narrative23users have liked this narrative2users have commented on this narrative58users have followed this narrativeRead narrativeProteome Sciences plc 競合他社Fusion AntibodiesSymbol: AIM:FABMarket cap: UK£16.9mIXICOSymbol: AIM:IXIMarket cap: UK£14.4mPhysiomicsSymbol: AIM:PYCMarket cap: UK£2.5mOxford BioDynamicsSymbol: AIM:OBDMarket cap: UK£7.7m価格と性能株価の高値、安値、推移の概要Proteome Sciences過去の株価現在の株価UK£0.01452週高値UK£0.04452週安値UK£0.012ベータ0.221ヶ月の変化-11.39%3ヶ月変化-21.13%1年変化-54.69%3年間の変化-67.74%5年間の変化-83.18%IPOからの変化-99.13%最新ニュースお知らせ • Apr 17Proteome Sciences plc Announces Directorate Change with the Departure of Non-Executive Director Roger McdowellProteome Sciences plc announced that Roger McDowell, after 11 years on the Board as a non-executive director, believes it is the right time for him to step down and to not seek re-election at the upcoming Annual General Meeting. Roger McDowell departs from the Board as a non-executive director.Reported Earnings • Apr 16Full year 2025 earnings released: UK£0.01 loss per share (vs UK£0.012 loss in FY 2024)Full year 2025 results: UK£0.01 loss per share (improved from UK£0.012 loss in FY 2024). Revenue: UK£3.76m (down 23% from FY 2024). Net loss: UK£3.06m (loss narrowed 10% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 62% per year but the company’s share price has only fallen by 30% per year, which means it has not declined as severely as earnings.お知らせ • Apr 15Proteome Sciences plc, Annual General Meeting, May 14, 2026Proteome Sciences plc, Annual General Meeting, May 14, 2026. Location: sp angel corporate finance llp, prince frederick house, 35 39 maddox street, w1s 2pp, london United KingdomNew Risk • Apr 13New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-UK£8.6m). Earnings have declined by 64% per year over the past 5 years. Market cap is less than US$10m (UK£5.54m market cap, or US$7.46m). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Shareholders have been diluted in the past year (19% increase in shares outstanding).New Risk • Jan 30New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (23% average weekly change). Negative equity (-UK£8.6m). Earnings have declined by 64% per year over the past 5 years. Market cap is less than US$10m (UK£6.86m market cap, or US$9.46m). Minor Risk Shareholders have been diluted in the past year (16% increase in shares outstanding).お知らせ • Jan 29Proteome Sciences plc has completed a Follow-on Equity Offering in the amount of £0.132 million.Proteome Sciences plc has completed a Follow-on Equity Offering in the amount of £0.132 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 7,542,856 Price\Range: £0.0175 Transaction Features: Regulation S最新情報をもっと見るRecent updatesお知らせ • Apr 17Proteome Sciences plc Announces Directorate Change with the Departure of Non-Executive Director Roger McdowellProteome Sciences plc announced that Roger McDowell, after 11 years on the Board as a non-executive director, believes it is the right time for him to step down and to not seek re-election at the upcoming Annual General Meeting. Roger McDowell departs from the Board as a non-executive director.Reported Earnings • Apr 16Full year 2025 earnings released: UK£0.01 loss per share (vs UK£0.012 loss in FY 2024)Full year 2025 results: UK£0.01 loss per share (improved from UK£0.012 loss in FY 2024). Revenue: UK£3.76m (down 23% from FY 2024). Net loss: UK£3.06m (loss narrowed 10% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 62% per year but the company’s share price has only fallen by 30% per year, which means it has not declined as severely as earnings.お知らせ • Apr 15Proteome Sciences plc, Annual General Meeting, May 14, 2026Proteome Sciences plc, Annual General Meeting, May 14, 2026. Location: sp angel corporate finance llp, prince frederick house, 35 39 maddox street, w1s 2pp, london United KingdomNew Risk • Apr 13New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-UK£8.6m). Earnings have declined by 64% per year over the past 5 years. Market cap is less than US$10m (UK£5.54m market cap, or US$7.46m). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Shareholders have been diluted in the past year (19% increase in shares outstanding).New Risk • Jan 30New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (23% average weekly change). Negative equity (-UK£8.6m). Earnings have declined by 64% per year over the past 5 years. Market cap is less than US$10m (UK£6.86m market cap, or US$9.46m). Minor Risk Shareholders have been diluted in the past year (16% increase in shares outstanding).お知らせ • Jan 29Proteome Sciences plc has completed a Follow-on Equity Offering in the amount of £0.132 million.Proteome Sciences plc has completed a Follow-on Equity Offering in the amount of £0.132 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 7,542,856 Price\Range: £0.0175 Transaction Features: Regulation Sお知らせ • Jan 26Proteome Sciences plc has completed a Follow-on Equity Offering in the amount of £0.84 million.Proteome Sciences plc has completed a Follow-on Equity Offering in the amount of £0.84 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 29,428,572 Price\Range: £0.0175 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 18,571,428 Price\Range: £0.0175 Transaction Features: Subsequent Direct ListingReported Earnings • Sep 28First half 2025 earnings released: UK£0.007 loss per share (vs UK£0.007 loss in 1H 2024)First half 2025 results: UK£0.007 loss per share (in line with 1H 2024). Revenue: UK£1.86m (down 16% from 1H 2024). Net loss: UK£2.14m (loss narrowed 3.3% from 1H 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 63 percentage points per year, which is a significant difference in performance.New Risk • Sep 25New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: UK£5.18m (US$6.91m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.5m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-UK£8.6m). Earnings have declined by 64% per year over the past 5 years. Market cap is less than US$10m (UK£5.18m market cap, or US$6.91m).New Risk • May 22New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.0m free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Negative equity (-UK£6.5m). Earnings have declined by 64% per year over the past 5 years. Minor Risk Market cap is less than US$100m (UK£10.5m market cap, or US$14.1m).Reported Earnings • Apr 11Full year 2024 earnings released: UK£0.011 loss per share (vs UK£0.008 loss in FY 2023)Full year 2024 results: UK£0.011 loss per share (further deteriorated from UK£0.008 loss in FY 2023). Revenue: UK£4.89m (down 2.8% from FY 2023). Net loss: UK£3.41m (loss widened 39% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 97 percentage points per year, which is a significant difference in performance.お知らせ • Apr 10Proteome Sciences plc, Annual General Meeting, May 16, 2025Proteome Sciences plc, Annual General Meeting, May 16, 2025. Location: allenby capital, 5 st helens place, ec3a 6ab, london United Kingdomお知らせ • Apr 04Proteome Sciences plc to Report Fiscal Year 2024 Results on Apr 10, 2025Proteome Sciences plc announced that they will report fiscal year 2024 results at 8:00 AM, GMT Standard Time on Apr 10, 2025New Risk • Apr 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Negative equity (-UK£5.3m). Earnings have declined by 49% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (UK£12.0m market cap, or US$15.5m).New Risk • Jan 02New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: UK£4.0m (US$5.0m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Negative equity (-UK£5.3m). Earnings have declined by 49% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Revenue is less than US$5m (UK£4.0m revenue, or US$5.0m). Market cap is less than US$100m (UK£10.0m market cap, or US$12.4m).New Risk • Nov 01New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: UK£7.38m (US$9.53m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Negative equity (-UK£5.3m). Earnings have declined by 49% per year over the past 5 years. Market cap is less than US$10m (UK£7.38m market cap, or US$9.53m).New Risk • Sep 20New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: UK£7.38m (US$9.83m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Negative equity (-UK£5.3m). Earnings have declined by 49% per year over the past 5 years. Market cap is less than US$10m (UK£7.38m market cap, or US$9.83m).New Risk • Sep 14New major risk - Revenue and earnings growthEarnings have declined by 49% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-UK£5.3m). Earnings have declined by 49% per year over the past 5 years. Minor Risk Market cap is less than US$100m (UK£8.41m market cap, or US$11.0m).お知らせ • Sep 13Proteome Sciences plc Announces Step Down of Dr Mariola Soehngen as Chief Executive Officer at the End of January 2025Proteome Sciences plc announced that Dr Mariola Soehngen has notified the Company of her intention to step down as Chief Executive Officer of the Company after four years of service at the end of January 2025. The process to appoint a successor has been initiated.分析記事 • May 10Here's Why Shareholders Should Examine Proteome Sciences plc's (LON:PRM) CEO Compensation Package More CloselyKey Insights Proteome Sciences to hold its Annual General Meeting on 16th of May CEO Mariola Sohngen's total...New Risk • Apr 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Negative equity (-UK£3.1m). Minor Risk Market cap is less than US$100m (UK£9.06m market cap, or US$11.3m).Reported Earnings • Apr 10Full year 2023 earnings released: UK£0.008 loss per share (vs UK£0.004 profit in FY 2022)Full year 2023 results: UK£0.008 loss per share (down from UK£0.004 profit in FY 2022). Revenue: UK£5.03m (down 35% from FY 2022). Net loss: UK£2.44m (down 284% from profit in FY 2022). Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings.お知らせ • Apr 10Proteome Sciences plc, Annual General Meeting, May 16, 2024Proteome Sciences plc, Annual General Meeting, May 16, 2024, at 11:00 Coordinated Universal Time. Location: Allenby Capital, 5 St Helen's Place, London United KingdomNew Risk • Mar 12New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.0x net interest cover). Negative equity (-UK£1.4m). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Share price has been volatile over the past 3 months (7.9% average weekly change). Market cap is less than US$100m (UK£12.2m market cap, or US$15.6m).New Risk • Feb 06New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.0x net interest cover). Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-UK£1.4m). Minor Risk Market cap is less than US$100m (UK£13.3m market cap, or US$16.7m).分析記事 • Dec 02Here's Why We Think Proteome Sciences (LON:PRM) Is Well Worth WatchingFor beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...お知らせ • Oct 05Proteome Sciences plc Announces the Launch of Sysquant® SCP, the Commercial Service for Single Cell Proteomics Using the Power of its TMTpro™ Isobaric Labelling ReagentsProteome Sciences plc announced the launch of SysQuant® SCP, the commercial service for single cell proteomics using the power of its TMTpro™ isobaric labelling reagents. Where more traditional approaches can measure a few 10s of proteins on each cell using antibody labelling, SysQuant® SCP can identify more than 1,000 proteins in each study of 576 single cells and provides novel insights into individual cell biology and heterogeneity. Proteome Sciences is one of the first commercial providers of such studies whichare expected to significantly improve the performance of drug development across multiple diseases including cancer, neurodegeneration, respiratory and cardiac health, and metabolic disorders. Whilst in its infancy, the field of single cell proteomics is expected to grow rapidly as drug developers look to integrate single cell genomic data with knowledge of protein changes. At the same time, the complexity of the process along with the need to purchase and maintain costly equipment represents a significant barrier to entry. The SysQuant® SCP pipeline generates and analyses quantitative mass spectrometry data to reveal subtle changes not only in individual cells but also within sub-populations of that same main cell type. This data will greatly improve understanding of the biological drivers of heterogeneity and evolution in the contexts of disease and response to therapy, which will offer new therapeutic and diagnostic targets for personalized medicine.Reported Earnings • Aug 26First half 2023 earnings released: UK£0.002 loss per share (vs UK£0 in 1H 2022)First half 2023 results: UK£0.002 loss per share (further deteriorated from UK£0 in 1H 2022). Revenue: UK£3.21m (down 1.0% from 1H 2022). Net loss: UK£578.0k (down UK£641.0k from profit in 1H 2022). Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.Buying Opportunity • Aug 26Now 43% undervaluedOver the last 90 days, the stock is up 7.8%. The fair value is estimated to be UK£0.095, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 64%.分析記事 • Aug 25Here's Why Proteome Sciences (LON:PRM) Has Caught The Eye Of InvestorsFor beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Reported Earnings • Apr 08Full year 2022 earnings released: EPS: UK£0.004 (vs UK£0 in FY 2021)Full year 2022 results: EPS: UK£0.004 (up from UK£0 in FY 2021). Revenue: UK£7.78m (up 52% from FY 2021). Net income: UK£1.33m (up UK£1.25m from FY 2021). Profit margin: 17% (up from 1.4% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 76% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.分析記事 • Dec 22Here's Why Proteome Sciences (LON:PRM) Has Caught The Eye Of InvestorsIt's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Non-Executive Director Ursula Ney was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.分析記事 • Sep 03Do Proteome Sciences' (LON:PRM) Earnings Warrant Your Attention?Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Reported Earnings • Aug 05First half 2022 earnings releasedFirst half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (up UK£425.0k from 1H 2021). Profit margin: (up from net loss in 1H 2021). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 75% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.Board Change • Apr 27Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 9 experienced directors. 2 highly experienced directors. 2 independent directors (5 non-independent directors). Independent Non-Executive Director Ursula Ney was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Apr 01Full year 2021 earnings released: EPS: UK£0 (vs UK£0.001 in FY 2020)Full year 2021 results: EPS: UK£0 (down from UK£0.001 in FY 2020). Revenue: UK£5.13m (up 7.9% from FY 2020). Net income: UK£72.0k (down 76% from FY 2020). Profit margin: 1.4% (down from 6.2% in FY 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 118% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.Buying Opportunity • Mar 29Now 25% undervalued after recent price dropOver the last 90 days, the stock is down 31%. The fair value is estimated to be UK£0.048, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% per annum over the last 3 years. The company has become profitable over the last 3 years.Buying Opportunity • Mar 10Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 29%. The fair value is estimated to be UK£0.047, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% per annum over the last 3 years. The company has become profitable over the last 3 years.Buying Opportunity • Feb 22Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 27%. The fair value is estimated to be UK£0.054, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% per annum over the last 3 years. The company has become profitable over the last 3 years.分析記事 • Jan 27Calculating The Fair Value Of Proteome Sciences plc (LON:PRM)Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Proteome Sciences plc...Reported Earnings • Aug 03First half 2021 earnings released: UK£0.001 loss per share (vs UK£0.002 loss in 1H 2020)The company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: UK£1.97m (up 3.7% from 1H 2020). Net loss: UK£425.0k (loss narrowed 17% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 131% per year but the company’s share price has only increased by 17% per year, which means it is significantly lagging earnings growth.分析記事 • May 31Does Proteome Sciences (LON:PRM) Deserve A Spot On Your Watchlist?Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...分析記事 • Apr 04Some Confidence Is Lacking In Proteome Sciences plc's (LON:PRM) P/EProteome Sciences plc's ( LON:PRM ) price-to-earnings (or "P/E") ratio of 40x might make it look like a strong sell...Reported Earnings • Apr 03Full year 2020 earnings released: EPS UK£0.001 (vs UK£0.001 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: UK£4.75m (up 2.1% from FY 2019). Net income: UK£295.0k (up 98% from FY 2019). Profit margin: 6.2% (up from 3.2% in FY 2019). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 112% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.株主還元PRMGB Life SciencesGB 市場7D-16.7%-2.7%-0.8%1Y-54.7%-11.6%19.7%株主還元を見る業界別リターン: PRM過去 1 年間で-11.6 % の収益を上げたUK Life Sciences業界を下回りました。リターン対市場: PRMは、過去 1 年間で19.7 % のリターンを上げたUK市場を下回りました。価格変動Is PRM's price volatile compared to industry and market?PRM volatilityPRM Average Weekly Movement10.4%Life Sciences Industry Average Movement8.9%Market Average Movement5.6%10% most volatile stocks in GB Market11.6%10% least volatile stocks in GB Market3.1%安定した株価: PRMの株価は、 UK市場と比較して過去 3 か月間で変動しています。時間の経過による変動: PRMの 週次ボラティリティ は過去 1 年間で17%から10%に減少しましたが、依然としてUK株の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト199332n/awww.proteomics.comProteome Sciences plc は、米国、英国、欧州連合、および国際的に、タンパク質バイオマーカーの同定、検証、応用のための受託研究サービスを提供している。リン酸化ペプチドの濃縮が不要な細胞や組織の標準分析法であるTMT LC-MS2、定量精度が重要な血漿やその他のサンプルのバイオマーカー探索のための標準分析法であるTMT LC-MS3、制御経路やシグナル伝達経路にわたるタンパク質活性の分析を提供するSysQuant、疾患組織や治療組織を末梢液と並行して分析できるTMTcalibratorを提供している。また、血清や血漿からのタンパク質のトップ14およびトップ65のスーパーデプリーション、選択的反応モニタリング（SRM）および並列反応モニタリング（PRM）に基づくバイオマーカーアッセイ開発、バイオマーカーのルーチン測定のための標的質量分析アッセイフォーマットであるSRMアッセイ、バイオマーカー候補の迅速なバリデーションを可能にする標的アッセイフォーマットであるTMT SRMも提供している。製薬会社、バイオテクノロジー企業、学術研究機関に製品を提供している。同社は1993年に設立され、英国コブハムを拠点としている。もっと見るProteome Sciences plc 基礎のまとめProteome Sciences の収益と売上を時価総額と比較するとどうか。PRM 基礎統計学時価総額UK£4.91m収益（TTM）-UK£3.06m売上高(TTM)UK£3.76m1.3xP/Sレシオ-1.6xPER（株価収益率PRM は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計PRM 損益計算書（TTM）収益UK£3.76m売上原価UK£3.84m売上総利益-UK£81.00kその他の費用UK£2.98m収益-UK£3.06m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.0087グロス・マージン-2.16%純利益率-81.50%有利子負債／自己資本比率-151.7%PRM の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/11 13:50終値2026/05/08 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Proteome Sciences plc 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関null nullCavendishMichael Thomas CooperEdison Investment Research
Featured narrative•Pharmaceuticals & Biotech opportunityGain Therapeuticsabout 1 month ago author updated this narrativeLOFair Value from Lou_BaseneseUS$7.676.1% 割安 内在価値ディスカウントThe Market Is Sleeping on This Parkinson's Biotech - And I Think That's a MistakeGain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read full narrative4kusers have viewed this narrative23users have liked this narrative2users have commented on this narrative58users have followed this narrativeRead narrative
お知らせ • Apr 17Proteome Sciences plc Announces Directorate Change with the Departure of Non-Executive Director Roger McdowellProteome Sciences plc announced that Roger McDowell, after 11 years on the Board as a non-executive director, believes it is the right time for him to step down and to not seek re-election at the upcoming Annual General Meeting. Roger McDowell departs from the Board as a non-executive director.
Reported Earnings • Apr 16Full year 2025 earnings released: UK£0.01 loss per share (vs UK£0.012 loss in FY 2024)Full year 2025 results: UK£0.01 loss per share (improved from UK£0.012 loss in FY 2024). Revenue: UK£3.76m (down 23% from FY 2024). Net loss: UK£3.06m (loss narrowed 10% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 62% per year but the company’s share price has only fallen by 30% per year, which means it has not declined as severely as earnings.
お知らせ • Apr 15Proteome Sciences plc, Annual General Meeting, May 14, 2026Proteome Sciences plc, Annual General Meeting, May 14, 2026. Location: sp angel corporate finance llp, prince frederick house, 35 39 maddox street, w1s 2pp, london United Kingdom
New Risk • Apr 13New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-UK£8.6m). Earnings have declined by 64% per year over the past 5 years. Market cap is less than US$10m (UK£5.54m market cap, or US$7.46m). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Shareholders have been diluted in the past year (19% increase in shares outstanding).
New Risk • Jan 30New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (23% average weekly change). Negative equity (-UK£8.6m). Earnings have declined by 64% per year over the past 5 years. Market cap is less than US$10m (UK£6.86m market cap, or US$9.46m). Minor Risk Shareholders have been diluted in the past year (16% increase in shares outstanding).
お知らせ • Jan 29Proteome Sciences plc has completed a Follow-on Equity Offering in the amount of £0.132 million.Proteome Sciences plc has completed a Follow-on Equity Offering in the amount of £0.132 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 7,542,856 Price\Range: £0.0175 Transaction Features: Regulation S
お知らせ • Apr 17Proteome Sciences plc Announces Directorate Change with the Departure of Non-Executive Director Roger McdowellProteome Sciences plc announced that Roger McDowell, after 11 years on the Board as a non-executive director, believes it is the right time for him to step down and to not seek re-election at the upcoming Annual General Meeting. Roger McDowell departs from the Board as a non-executive director.
Reported Earnings • Apr 16Full year 2025 earnings released: UK£0.01 loss per share (vs UK£0.012 loss in FY 2024)Full year 2025 results: UK£0.01 loss per share (improved from UK£0.012 loss in FY 2024). Revenue: UK£3.76m (down 23% from FY 2024). Net loss: UK£3.06m (loss narrowed 10% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 62% per year but the company’s share price has only fallen by 30% per year, which means it has not declined as severely as earnings.
お知らせ • Apr 15Proteome Sciences plc, Annual General Meeting, May 14, 2026Proteome Sciences plc, Annual General Meeting, May 14, 2026. Location: sp angel corporate finance llp, prince frederick house, 35 39 maddox street, w1s 2pp, london United Kingdom
New Risk • Apr 13New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-UK£8.6m). Earnings have declined by 64% per year over the past 5 years. Market cap is less than US$10m (UK£5.54m market cap, or US$7.46m). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Shareholders have been diluted in the past year (19% increase in shares outstanding).
New Risk • Jan 30New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (23% average weekly change). Negative equity (-UK£8.6m). Earnings have declined by 64% per year over the past 5 years. Market cap is less than US$10m (UK£6.86m market cap, or US$9.46m). Minor Risk Shareholders have been diluted in the past year (16% increase in shares outstanding).
お知らせ • Jan 29Proteome Sciences plc has completed a Follow-on Equity Offering in the amount of £0.132 million.Proteome Sciences plc has completed a Follow-on Equity Offering in the amount of £0.132 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 7,542,856 Price\Range: £0.0175 Transaction Features: Regulation S
お知らせ • Jan 26Proteome Sciences plc has completed a Follow-on Equity Offering in the amount of £0.84 million.Proteome Sciences plc has completed a Follow-on Equity Offering in the amount of £0.84 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 29,428,572 Price\Range: £0.0175 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 18,571,428 Price\Range: £0.0175 Transaction Features: Subsequent Direct Listing
Reported Earnings • Sep 28First half 2025 earnings released: UK£0.007 loss per share (vs UK£0.007 loss in 1H 2024)First half 2025 results: UK£0.007 loss per share (in line with 1H 2024). Revenue: UK£1.86m (down 16% from 1H 2024). Net loss: UK£2.14m (loss narrowed 3.3% from 1H 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 63 percentage points per year, which is a significant difference in performance.
New Risk • Sep 25New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: UK£5.18m (US$6.91m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.5m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-UK£8.6m). Earnings have declined by 64% per year over the past 5 years. Market cap is less than US$10m (UK£5.18m market cap, or US$6.91m).
New Risk • May 22New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.0m free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Negative equity (-UK£6.5m). Earnings have declined by 64% per year over the past 5 years. Minor Risk Market cap is less than US$100m (UK£10.5m market cap, or US$14.1m).
Reported Earnings • Apr 11Full year 2024 earnings released: UK£0.011 loss per share (vs UK£0.008 loss in FY 2023)Full year 2024 results: UK£0.011 loss per share (further deteriorated from UK£0.008 loss in FY 2023). Revenue: UK£4.89m (down 2.8% from FY 2023). Net loss: UK£3.41m (loss widened 39% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 97 percentage points per year, which is a significant difference in performance.
お知らせ • Apr 10Proteome Sciences plc, Annual General Meeting, May 16, 2025Proteome Sciences plc, Annual General Meeting, May 16, 2025. Location: allenby capital, 5 st helens place, ec3a 6ab, london United Kingdom
お知らせ • Apr 04Proteome Sciences plc to Report Fiscal Year 2024 Results on Apr 10, 2025Proteome Sciences plc announced that they will report fiscal year 2024 results at 8:00 AM, GMT Standard Time on Apr 10, 2025
New Risk • Apr 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Negative equity (-UK£5.3m). Earnings have declined by 49% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (UK£12.0m market cap, or US$15.5m).
New Risk • Jan 02New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: UK£4.0m (US$5.0m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Negative equity (-UK£5.3m). Earnings have declined by 49% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Revenue is less than US$5m (UK£4.0m revenue, or US$5.0m). Market cap is less than US$100m (UK£10.0m market cap, or US$12.4m).
New Risk • Nov 01New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: UK£7.38m (US$9.53m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Negative equity (-UK£5.3m). Earnings have declined by 49% per year over the past 5 years. Market cap is less than US$10m (UK£7.38m market cap, or US$9.53m).
New Risk • Sep 20New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: UK£7.38m (US$9.83m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Negative equity (-UK£5.3m). Earnings have declined by 49% per year over the past 5 years. Market cap is less than US$10m (UK£7.38m market cap, or US$9.83m).
New Risk • Sep 14New major risk - Revenue and earnings growthEarnings have declined by 49% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-UK£5.3m). Earnings have declined by 49% per year over the past 5 years. Minor Risk Market cap is less than US$100m (UK£8.41m market cap, or US$11.0m).
お知らせ • Sep 13Proteome Sciences plc Announces Step Down of Dr Mariola Soehngen as Chief Executive Officer at the End of January 2025Proteome Sciences plc announced that Dr Mariola Soehngen has notified the Company of her intention to step down as Chief Executive Officer of the Company after four years of service at the end of January 2025. The process to appoint a successor has been initiated.
分析記事 • May 10Here's Why Shareholders Should Examine Proteome Sciences plc's (LON:PRM) CEO Compensation Package More CloselyKey Insights Proteome Sciences to hold its Annual General Meeting on 16th of May CEO Mariola Sohngen's total...
New Risk • Apr 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Negative equity (-UK£3.1m). Minor Risk Market cap is less than US$100m (UK£9.06m market cap, or US$11.3m).
Reported Earnings • Apr 10Full year 2023 earnings released: UK£0.008 loss per share (vs UK£0.004 profit in FY 2022)Full year 2023 results: UK£0.008 loss per share (down from UK£0.004 profit in FY 2022). Revenue: UK£5.03m (down 35% from FY 2022). Net loss: UK£2.44m (down 284% from profit in FY 2022). Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings.
お知らせ • Apr 10Proteome Sciences plc, Annual General Meeting, May 16, 2024Proteome Sciences plc, Annual General Meeting, May 16, 2024, at 11:00 Coordinated Universal Time. Location: Allenby Capital, 5 St Helen's Place, London United Kingdom
New Risk • Mar 12New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.0x net interest cover). Negative equity (-UK£1.4m). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Share price has been volatile over the past 3 months (7.9% average weekly change). Market cap is less than US$100m (UK£12.2m market cap, or US$15.6m).
New Risk • Feb 06New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.0x net interest cover). Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-UK£1.4m). Minor Risk Market cap is less than US$100m (UK£13.3m market cap, or US$16.7m).
分析記事 • Dec 02Here's Why We Think Proteome Sciences (LON:PRM) Is Well Worth WatchingFor beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
お知らせ • Oct 05Proteome Sciences plc Announces the Launch of Sysquant® SCP, the Commercial Service for Single Cell Proteomics Using the Power of its TMTpro™ Isobaric Labelling ReagentsProteome Sciences plc announced the launch of SysQuant® SCP, the commercial service for single cell proteomics using the power of its TMTpro™ isobaric labelling reagents. Where more traditional approaches can measure a few 10s of proteins on each cell using antibody labelling, SysQuant® SCP can identify more than 1,000 proteins in each study of 576 single cells and provides novel insights into individual cell biology and heterogeneity. Proteome Sciences is one of the first commercial providers of such studies whichare expected to significantly improve the performance of drug development across multiple diseases including cancer, neurodegeneration, respiratory and cardiac health, and metabolic disorders. Whilst in its infancy, the field of single cell proteomics is expected to grow rapidly as drug developers look to integrate single cell genomic data with knowledge of protein changes. At the same time, the complexity of the process along with the need to purchase and maintain costly equipment represents a significant barrier to entry. The SysQuant® SCP pipeline generates and analyses quantitative mass spectrometry data to reveal subtle changes not only in individual cells but also within sub-populations of that same main cell type. This data will greatly improve understanding of the biological drivers of heterogeneity and evolution in the contexts of disease and response to therapy, which will offer new therapeutic and diagnostic targets for personalized medicine.
Reported Earnings • Aug 26First half 2023 earnings released: UK£0.002 loss per share (vs UK£0 in 1H 2022)First half 2023 results: UK£0.002 loss per share (further deteriorated from UK£0 in 1H 2022). Revenue: UK£3.21m (down 1.0% from 1H 2022). Net loss: UK£578.0k (down UK£641.0k from profit in 1H 2022). Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth.
Buying Opportunity • Aug 26Now 43% undervaluedOver the last 90 days, the stock is up 7.8%. The fair value is estimated to be UK£0.095, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 64%.
分析記事 • Aug 25Here's Why Proteome Sciences (LON:PRM) Has Caught The Eye Of InvestorsFor beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Reported Earnings • Apr 08Full year 2022 earnings released: EPS: UK£0.004 (vs UK£0 in FY 2021)Full year 2022 results: EPS: UK£0.004 (up from UK£0 in FY 2021). Revenue: UK£7.78m (up 52% from FY 2021). Net income: UK£1.33m (up UK£1.25m from FY 2021). Profit margin: 17% (up from 1.4% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 76% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
分析記事 • Dec 22Here's Why Proteome Sciences (LON:PRM) Has Caught The Eye Of InvestorsIt's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Non-Executive Director Ursula Ney was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
分析記事 • Sep 03Do Proteome Sciences' (LON:PRM) Earnings Warrant Your Attention?Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Reported Earnings • Aug 05First half 2022 earnings releasedFirst half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (up UK£425.0k from 1H 2021). Profit margin: (up from net loss in 1H 2021). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 75% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
Board Change • Apr 27Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 9 experienced directors. 2 highly experienced directors. 2 independent directors (5 non-independent directors). Independent Non-Executive Director Ursula Ney was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Apr 01Full year 2021 earnings released: EPS: UK£0 (vs UK£0.001 in FY 2020)Full year 2021 results: EPS: UK£0 (down from UK£0.001 in FY 2020). Revenue: UK£5.13m (up 7.9% from FY 2020). Net income: UK£72.0k (down 76% from FY 2020). Profit margin: 1.4% (down from 6.2% in FY 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 118% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.
Buying Opportunity • Mar 29Now 25% undervalued after recent price dropOver the last 90 days, the stock is down 31%. The fair value is estimated to be UK£0.048, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% per annum over the last 3 years. The company has become profitable over the last 3 years.
Buying Opportunity • Mar 10Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 29%. The fair value is estimated to be UK£0.047, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% per annum over the last 3 years. The company has become profitable over the last 3 years.
Buying Opportunity • Feb 22Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 27%. The fair value is estimated to be UK£0.054, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% per annum over the last 3 years. The company has become profitable over the last 3 years.
分析記事 • Jan 27Calculating The Fair Value Of Proteome Sciences plc (LON:PRM)Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Proteome Sciences plc...
Reported Earnings • Aug 03First half 2021 earnings released: UK£0.001 loss per share (vs UK£0.002 loss in 1H 2020)The company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: UK£1.97m (up 3.7% from 1H 2020). Net loss: UK£425.0k (loss narrowed 17% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 131% per year but the company’s share price has only increased by 17% per year, which means it is significantly lagging earnings growth.
分析記事 • May 31Does Proteome Sciences (LON:PRM) Deserve A Spot On Your Watchlist?Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
分析記事 • Apr 04Some Confidence Is Lacking In Proteome Sciences plc's (LON:PRM) P/EProteome Sciences plc's ( LON:PRM ) price-to-earnings (or "P/E") ratio of 40x might make it look like a strong sell...
Reported Earnings • Apr 03Full year 2020 earnings released: EPS UK£0.001 (vs UK£0.001 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: UK£4.75m (up 2.1% from FY 2019). Net income: UK£295.0k (up 98% from FY 2019). Profit margin: 6.2% (up from 3.2% in FY 2019). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 112% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.
